PLX-61639 vs PRT3789

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: SMARCA2 · full Non-Small Cell Lung Cancer pipeline

PLX-61639

Developed by Plexium, Inc.

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

PRT3789

Developed by Prelude Therapeutics

Phase 2 in Non-Small Cell Lung Cancerprotein degrader
Weak signal

NCT05639751 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Dose limiting toxicity (DLT) of PRT3789 monotherapy and in combination with docetaxel (Baseline through Day 21); Safety and tolerability of PRT3789 monotherapy and in combination with docetaxel: AEs, CTCAE Assessments (Baseline through approximately 3 years); Maximum tolerated dose (MTD)/ Recommended phase 2 dose (RP2D) of PRT3789 monotherapy and in combination with docetaxel (Baseline through approximately 3 years): PRT3789 (SMARCA2 degrader): well tolerated through 8 cohorts, no DLTs identified, no MTD reached; 3 confirmed PRs and 7/26 with tumor shrinkage in heavily pretreated NSCLC/esophageal patients (Aug 2024 data cutoff, 65 safety-evaluable)

Result source: NCT05639751

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPLX-61639PRT3789
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

PLX-61639
—Not reported
PRT3789
—Not reported

OS, median

PLX-61639
—Not reported
PRT3789
—Not reported

ORR

PLX-61639
—Not reported
PRT3789
—Not reported

Duration of response, median

PLX-61639
—Not reported
PRT3789
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

PLX-61639: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

PRT3789
PRT3789 (SMARCA2 degrader): well tolerated through 8 cohorts, no DLTs identified, no MTD reached; 3 confirmed PRs and 7/26 with tumor shrinkage in heavily pretreated NSCLC/esophageal patients (Aug 2024 data cutoff, 65 safety-evaluable) NCT05639751 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PLX-61639's landscape · PRT3789's landscape